ACPU
AZN icon

Arrowgrass Capital Partners (US)’s AstraZeneca AZN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-300,000
Closed -$15.6M – 157
2013
Q3 		$15.6M Buy
+300,000
New +$15.1M 0.58% 46

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s AZN Position: Q4 2014 in Review

Arrowgrass Capital Partners (US) sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 55,727 shares — an estimated $3.98M sold.

Arrowgrass Capital Partners (US) first reported a position in AZN in Q3 2013 and held it in 4 quarters. The position peaked at $26.4M in Q3 2013. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

  • Arrowgrass Capital Partners (US) reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 55,727 AstraZeneca shares in Q4 2014, an estimated $3.98M.
  • Arrowgrass Capital Partners (US) first reported a position in AstraZeneca in Q3 2013 and held it in 4 quarters.
  • Arrowgrass Capital Partners (US)'s AstraZeneca position peaked at $26.4M in Q3 2013.
  • 404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2014, filed 18 Feb 2015.